Cardiovascular disease remains the leading global killer. Still, too many late-stage cardiology trials stumble, not for lack of biology, but because episodic, clinic-bound measures miss what matters ...
A few months back, good news hit the multiple myeloma community: the U.S. Food & Drug Administration voted to accept a new endpoint — MRD, or measurable residual disease — for accelerated approval of ...
Less than half of the recent trials testing therapies for atherosclerotic cardiovascular disease (ASCVD) use the same endpoint, and many alter those endpoints after enrollment begins, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results